2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1722

Patient-Level Factors Associated with Hospital Readmission Among Patients with Systemic Sclerosis Associated Pulmonary Hypertension

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1434

Patient-Proxy Agreement on Health-Related Quality of Life in Juvenile Fibromyalgia Syndrome

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

9:00AM-11:00AM: Abstract Number: 1178

Patients’ and Healthcare Professionals’ Resource Preferences for a Knowledge Translation Toolkit for Hip and Knee Replacement Rehabilitation

Health Services Research Poster II – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 1619

Patterns and Outcomes on As Patients Disease Activity Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and the Correlation between Disease Activity and Mental Health

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1163

Patterns of Depressive Symptoms before and after Surgery for Hip, Knee and Lumbar Spine Osteoarthritis

Epidemiology and Public Health Poster II – ARHP

9:00AM-11:00AM: Abstract Number: 1154

Patterns of Opioid Use and Patient Characteristics before Total Hip and Knee Replacement

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1461

Peptidylarginine Deiminase-4 Antibodies Are Not Associated with Worse RA Activity, Symptoms or Impacts

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1599

Performance of Referral Strategies for Spondyloarthritis: A Population-Based Nationwide Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1473

Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1681

Performance of the Proposed American College of Rheumatology / European League Against Rheumatism 2017 Classification Criteria for SLE in Adult and Juvenile Systemic Lupus Erythematosus and Other Anti-Nuclear Antibody Related Rheumatic Diseases

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1143

Periodontal Disease Is Associated with an Increased Risk of Ankylosing Spondylitis: A Systematic Review and Meta-Analysis

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1082

Peripheral Blood CD11c+ CD21- Age-Associated B Cells (ABCs) in Human Systemic Lupus Erythematosus Are Associated with Innate Type III Interferon and Disease Activity

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1236

Peripheral-Blood B-Cell Subset Disturbances in Whipple’s Disease

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1209

Peritenon Extensor Tendon Inflammation, Synovitis and Enthesopathy in Psoriastic Arthritis: What Is the Connection?

Imaging of Rheumatic Diseases Poster II: Ultrasound

9:00AM-11:00AM: Abstract Number: 1580

Persistent Serological Activity in Primary Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].